Paper Details

  1. Home
  2. Paper Details

A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States.

Author: CroghanIvana T, EbbertJon O, HaysJ Taylor, SchroederDarrell R, SeversonHerbert H

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Long-term use of smokeless tobacco (ST) increases the risk of oral and throat cancer, heart attacks, and strokes. While varenicline has been shown to help Swedish smokeless tobacco users quit, this study investigates whether it can also help people quit smokeless tobacco in the Midwestern United States.
Paper Details　
Original Abstract of the Article :
Long-term smokeless tobacco (ST) use is known to increase the risk for oropharyngeal cancer, heart attack, and stroke. Varenicline has recently been demonstrated to increase ST abstinence rates among Swedish snus users. We have conducted a pilot study to obtain preliminary evidence of efficacy of va...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168243/

データ提供：米国国立医学図書館（NLM）

Varenicline: A Potential Treatment for Smokeless Tobacco Users

The use of smokeless tobacco (ST) can be as harmful as a desert mirage, leading to serious health issues like oropharyngeal cancer, heart attack, and stroke. This research explores the potential of varenicline, a medication that helps people quit smoking, to aid ST users in their journey toward a healthier life. It investigates the effectiveness of varenicline in helping ST users break free from the allure of this dangerous habit. This study explores the potential of varenicline to help ST users navigate the desert of addiction and reach a healthier destination.

A Promising Oasis for Smokeless Tobacco Users

This pilot study offers promising preliminary evidence suggesting that varenicline could be an effective treatment option for ST users. This research indicates that varenicline may offer a path to a healthier lifestyle for ST users, helping them escape the clutches of addiction and improve their overall well-being.

Navigating the Desert of Addiction with Varenicline

This research offers hope for ST users seeking to break free from this harmful habit. Varenicline may provide a valuable tool for those looking to embark on a journey toward a healthier life. The study highlights the potential of varenicline to help ST users navigate the desert of addiction and reach a healthier destination.

Dr. Camel's Conclusion

This pilot study offers a glimpse of hope for ST users seeking to break free from addiction. Varenicline, a medication that has proven successful in helping people quit smoking, may also provide a pathway for ST users to escape the desert of this dangerous habit. It's a reminder that even in the vast and challenging landscape of addiction, there can be pathways toward a healthier future.

Date :
  1. Date Completed 2012-02-08
  2. Date Revised 2023-11-04
Further Info :

Pubmed ID

21504885

DOI: Digital Object Identifier

PMC3168243

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.